ML 141 CDC42 Inhibition for Bacterial Intracellular Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial infections caused by Staphylococcus aureus and Streptococcus pyogenes are hindered by antibiotic resistance and the ability of these pathogens to persist intracellularly, leading to chronic and recurrent infections, with existing therapies failing to effectively inhibit host cell invasion and persistence.
Innovation Solution
The compound ML 141, which selectively inhibits CDC42 by binding directly to it and preventing GTP-loading, thereby reducing host cell adhesion and intracellular persistence of these bacteria, is administered to cells to suppress microbial infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antibiotic treatments are used, then bacterial infection can be treated initially, but antibiotic resistance develops and intracellular persistence occurs leading to chronic infection
Solution Approach 1:
The patent extracts and targets the specific host cell mechanism (CDC42 GTPase) that bacteria exploit for intracellular invasion and persistence. By removing or inhibiting this specific host factor that bacteria depend on, the treatment prevents intracellular persistence without requiring direct antibacterial activity, thereby overcoming antibiotic resistance mechanisms.
Solution Approach 2:
The patent introduces an intermediary approach by targeting the host cell's CDC42 protein rather than the bacteria directly. This intermediary host factor serves as the mediator through which the treatment exerts its effect, blocking the bacterial invasion pathway indirectly and avoiding direct selection pressure that drives antibiotic resistance.
2Loss of time
If antibiotics are withdrawn after treatment, then short-term infection may be controlled, but bacteria persist intracellularly and cause recurrent infection months to years later
Solution Approach 1:
The patent applies preliminary action by blocking the CDC42-mediated invasion pathway before bacteria can establish intracellular persistence. By preventing the initial intracellular entry through CDC42 inhibition, the treatment eliminates the reservoir for chronic infection, ensuring that even after treatment withdrawal, no persistent bacterial population remains to cause recurrence.
3Reliability
If statins are used to inhibit CDC42 indirectly through mevalonate pathway, then some inhibition occurs, but the mechanism is non-specific and affects cholesterol biosynthesis
Solution Approach 1:
The patent applies local quality by creating a treatment that specifically targets CDC42 GTPase activity without affecting other cellular pathways. The approach focuses the inhibitory effect precisely on the CDC42 protein's GTP-binding function, leaving cholesterol biosynthesis and other mevalonate pathway functions untouched, thereby achieving high specificity.
Solution Approach 2:
The patent changes the parameter of inhibition mechanism from indirect mevalonate pathway blockade to direct CDC42 GTPase activity inhibition. This parameter change shifts the mode of action from affecting multiple downstream targets (including cholesterol synthesis) to specifically targeting the GTP-binding and GTPase activation of CDC42, achieving cleaner and more specific inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ML 141 significantly decreases host cell invasion and intracellular persistence of Staphylococcus aureus and Streptococcus pyogenes, offering a potential adjunctive therapeutic approach to current treatments by targeting CDC42, thus limiting chronic infection sources and impairing PI3K signaling pathways.
Implementation Method 1
ML 141 inhibits GTP-binding at the activation site of CDC42
Implementation Method 2
The mechanism of inhibition by ML 141 also includes decreasing host cell adhesion to fibronectin, the extracellular matrix protein used by S. aureus for gaining host cell entry
Data Source
AI summary
The present disclosure relates to molecules that function as selective modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases and, in particular, CDC42 GTPase, and their use to treat bacterial infection including systemic infection from sources such as Staphylococcus aureus and Streptococcus pyogenes.